Overview

Aztreonam for Inhalation (AI) in Patients With Cystic Fibrosis & P. Aeruginosa Infection

Status:
Completed
Trial end date:
2004-09-01
Target enrollment:
Participant gender:
Summary
This is multicenter placebo-controlled study evaluating the safety and efficacy of AI at two dosage levels compared to placebo in CF patients with P. aeruginosa lung infection.
Phase:
Phase 2
Details
Lead Sponsor:
Gilead Sciences
Collaborator:
Salus Pharma, Inc.
Treatments:
Aztreonam